oncgnostics GmbH

company

About

Oncgnostics develops IVD tests for screening, therapeutic decision making, and follow-up care in cancer diagnostics.

  • 1 - 10

Details

Last Funding Type
Series A
Industries
Biotechnology,Health Diagnostics,Medical,Robotics
Founded date
Feb 1, 2012
Number Of Employee
1 - 10
Operating Status
Active

oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable in vitro diagnostic (=IVD) tests for screening, therapeutic decisions and follow-up care in cancer diagnostics.

The diagnostic tests developed by oncgnostics are based on DNA regions specifically methylated in precancerous and carcinoma cells. These marker regions are detected using well-established PCR-based technologies, which can be performed in routine molecular diagnostics laboratories with standard equipment. oncgnostics has identified novel markers for detecting cervical precancerous lesions and carcinomas.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
oncgnostics GmbH has raised a total of — in funding over 2 rounds. Their latest funding was raised on Jan 29, 2015 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 29, 2015 Series A 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
oncgnostics GmbH is funded by 1 investors. Sparkasse Jena are the most recent investors.
Investor Name Lead Investor Funding Round
Sparkasse Jena Series A